Isis Calls Out Santaris Over Drug Development Deals
Drug developer Isis Pharmaceuticals Inc. slammed Santaris Pharma A/S Corp. with a patent infringement lawsuit Thursday, accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar...To view the full article, register now.
Already a subscriber? Click here to view full article